Aslan Pharmaceuticals announces first patient screened in study of eblasakimab

ASLAN Pharmaceuticals announced that it has screened the first patient in its TREK-DX study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis who have previously been treated with dupilumab. The randomized, double-blind, placebo-controlled, Phase 2 clinical trial is expected to enroll 75 patients in North America and will assess the efficacy and safety of eblasakimab in dupilumab experienced patients who have discontinued their treatment for any reason, including inadequate disease control, loss of access to drug or an adverse event. TREK-DX will enable ASLAN to test a once-weekly dosing regimen of 400mg of eblasakimab, which has previously been shown to be safe and well-tolerated in Phase 1 studies that may be the most effective option to address the severity and refractory nature of the disease that these patients experience. TREK-DX will provide support to TREK-AD, a trial that is investigating eblasakimab in biologic naive patients, and could help to strengthen the positioning of eblasakimab as the biologic of first choice for AD treatment. Topline data from TREK-DX is expected in the first quarter of 2024.